Contrasting Organogenesis (NASDAQ:ORGO) & GRAIL (NASDAQ:GRAL)

Organogenesis (NASDAQ:ORGO) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.

Valuation and Earnings

This table compares Organogenesis and GRAIL”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$349.58 million	0.34	$37.03 million	($1.22)	-0.77
GRAIL	$147.17 million	38.11	-$408.35 million	($9.50)	-13.13

Organogenesis has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

49.6% of Organogenesis shares are owned by institutional investors. 18.8% of Organogenesis shares are owned by company insiders. Comparatively, 1.8% of GRAIL shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Organogenesis has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, GRAIL has a beta of 2.86, meaning that its stock price is 186% more volatile than the S&P 500.

Profitability

This table compares Organogenesis and GRAIL’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Organogenesis	-39.34%	-55.28%	-23.72%
GRAIL	-243.80%	-16.13%	-14.38%

Analyst Recommendations

This is a summary of recent ratings for Organogenesis and GRAIL, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1	2	0	0	1.67
GRAIL	1	6	5	0	2.33

Organogenesis currently has a consensus price target of $4.33, indicating a potential upside of 363.36%. GRAIL has a consensus price target of $128.80, indicating a potential upside of 3.25%. Given Organogenesis’ higher possible upside, analysts clearly believe Organogenesis is more favorable than GRAIL.

Summary

Organogenesis beats GRAIL on 7 of the 13 factors compared between the two stocks.

About Organogenesis

Organogenesis Holdings Inc. is a biotechnology company that develops, manufactures and commercializes products intended to support tissue regeneration and wound healing. The company serves the advanced wound care and surgical and sports medicine markets, with a focus on therapies that help manage complex wounds and support the repair of damaged tissue. Its product portfolio includes bioengineered skin substitutes and other biologic products, such as Apligraf, Dermagraft, NuShield, Affinity and NuCel.

About GRAIL

GRAIL, Inc. is a healthcare company developing blood-based tests for the early detection of multiple cancers. Its approach analyzes patterns in cell-free DNA, including DNA methylation signals, to help identify a possible cancer signal and predict its origin in the body. GRAIL’s flagship product is Galleri, a multi-cancer early detection test intended for use alongside—not as a replacement for—recommended cancer screening. The company also conducts clinical research to evaluate the test and advance its early-detection technology.